Page 7 - Priyanka Chigurupati News Today : Breaking News, Live Updates & Top Stories | Vimarsana

USFDA closes observations on Granules India s arm - The Hindu BusinessLine

USFDA closes observations on Granules India s arm - The Hindu BusinessLine
thehindubusinessline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindubusinessline.com Daily Mail and Mail on Sunday newspapers.

United statesPriyanka chigurupatiGranules pharmaceuticals incDrug administrationGranules pharmaceuticalsGranules india ltdEstablishment inspection reportExecutive directorஒன்றுபட்டது மாநிலங்களில்பிரியாங்க சிகுருபடிதுகள்கள் மருந்துகள் இன்க்துகள்கள் மருந்துகள்துகள்கள் இந்தியா லிமிடெட்ஸ்தாபனம் ஆய்வு அறிக்கைநிர்வாகி இயக்குனர்

Granules Pharmaceuticals concludes FDA audit with two minor observations

Granules Pharmaceuticals concludes FDA audit with two minor observations
thehindubusinessline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindubusinessline.com Daily Mail and Mail on Sunday newspapers.

United statesAndhra pradeshPriyanka chigurupatiGranules pharmaceuticals incDrug administrationGranules pharmaceuticalsGranules indiaExecutive directorஒன்றுபட்டது மாநிலங்களில்ஆந்திரா பிரதேஷ்பிரியாங்க சிகுருபடிதுகள்கள் மருந்துகள் இன்க்துகள்கள் மருந்துகள்துகள்கள் இந்தியாநிர்வாகி இயக்குனர்

USFDA issues two observations after inspection of Granules India s Chantilly facility in US

"We will be responding to the two observations within the stipulated time period," Granules Pharmaceuticals Executive Director Priyanka Chigurupati said.

United statesPriyanka chigurupatiGranules pharmaceuticalsDrug administrationGranules indiaUnited states foodஒன்றுபட்டது மாநிலங்களில்பிரியாங்க சிகுருபடிதுகள்கள் மருந்துகள்துகள்கள் இந்தியாஒன்றுபட்டது மாநிலங்களில் உணவு

Granules India to invest Rs 1,000 crore over 3 years till FY24 to expand operations

Granules India to invest Rs 1,000 crore over 3 years till FY24 to expand operations The Hyderabad-based firm plans to invest in a new manufacturing facility and on expanding production capacities at existing plants PTI | May 16, 2021 | Updated 17:08 IST The company s revenue stood at Rs 3,238 crore for the 2020-21 financial year while its net profit was at Rs 549 crore for the period Drug firm Granules India has earmarked a capex of around Rs 1,000 crore which it aims to invest over the next three financial years on expansion of operations, according to a top company official. The Hyderabad-based firm plans to invest in a new manufacturing facility and on expanding production capacities at existing plants.

Andhra pradeshPriyanka chigurupatiKrishna prasad chigurupatiGranules indiaIndia chairmanManaging director krishna prasad chigurupatiMultiple units pellet systemIndia executive director priyanka chigurupatiGranules india newsRanules india capexRanules india capex newsRanules india covid 19Ranules india coronavirus newsRanules india investmentRanules india investment newsஆந்திரா பிரதேஷ்

New Drug for Migraine Approved

New Drug for Migraine Approved by Colleen Fleiss on February 25, 2021 at 8:03 AM The US Food & Drug Administration (US FDA) has approved Granules Abbreviated New Drug Application (ANDA) for acetaminophen, aspirin, and caffeine tablets, indicated for the treatment of migraine. It is bioequivalent to the Reference Listed Drug (RLD) product, Excedrin Migraine tablets, 250 mg/250 mg/65 mg, of GlaxoSmithKline Consumer Healthcare. The product would be manufactured at Granules India s Hyderabad facility and is expected to be launched shortly. ‘Granules Abbreviated New Drug Application (ANDA) for acetaminophen, aspirin, and caffeine tablets, indicated for migraine treatment has been approved by USFDA. ’ We are pleased to announce approval of Acetaminophen, Aspirin and Caffeine tablets, emphasising our focus on building a sustainable OTC product portfolio in the US market. We received approval for this triple combination product within 14 months from fi

Andhra pradeshPriyanka chigurupatiMigrainemenstrual migrainedrugGranules pharmaceuticals incUs food drug administrationDrug administrationGranule abbreviated new drug applicationReference listed drugExcedrin migraineGlaxosmithkline consumerGranules indiaExecutive directorGranules pharmaceuticalsToxicitymigraineclinical trialsSignature drug toxicityheadacheCephalgiadrugs banned